SIGN UP TO VIEW THE FULL ARTICLE

Receive a 90-day free trial of Celltelligence and get instant access to our full offering.


EMAIL BLASTS

Curated cell therapy industry news in your inbox multiple times each week

SEARCHABLE LIBRARY

A full archive of cell therapy news, insights, and context

THE MAP

A 24/7 information center that lets you make unique connections

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.

Account Information

LEAVE THIS BLANK

By selecting this, I agree to receive emails from celltelligence.com.

Already have an account? Log in here
RETURN TO HOME
$0
Allogeneic, BCMA, CAR-T

Why Poseida+Cellares Matters to Novartis; Poseida’s P-BCMA-ALLO1 Allogeneic Ph1 Trial in R/R MM

Here is a brief preview of this blast: On Wednesday, July 14, Cellares announced (press release) that Poseida Therapeutics has joined their Early Access Partnership Program (EAPP). Of note, the EAPP was created in 2020 to provide participants visibility and early access to Cellares’s Cell Shuttle manufacturing platform. On the same day, a new Poseida P-BCMA-ALLO1 (allogeneic BCMA CAR-T) Ph1 trial for r/r MM was observed on CT.gov. Below, Celltelligence provides insights on how Poseida's early access to the Cell Shuttle may increase the likelihood that Novartis could acquire Poseida as well as thoughts on Poseida’s new P-BCMA-ALLO1 Ph1 study.  

About The Author

The Celltelligence Team

|
Content Leads & Contributors
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.